Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 1/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 8/20 | 0.51 |
| ▸ | FFAR4 | Q5NUL3 | 7/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7799417 | 0.83 | FFAR4 (0.52) | FLT3FFAR1FFAR4CYP2C9CACNA1C | |
| SCHEMBL7795543 | 0.81 | TBXAS1 (0.53) | FFAR1FFAR4CYP2C9CACNA1CF2 | |
| SCHEMBL27511219 | 0.80 | FLT3 (0.47) | FLT3FFAR1FFAR4F2F10 | |
| Hydrochloric Acid SCHEMBL6983719 | 0.79 | FLT3 (0.46) | FLT3FFAR1FFAR4F2F10 | |
| SCHEMBL7248298 | 0.79 | LOXL2 (0.53) | FLT3FFAR1FFAR4CYP2C9CACNA1C | |
| SCHEMBL5221517 | 0.78 | HRH3 (0.49) | FFAR1FFAR4CYP2C9CACNA1C | |
| SCHEMBL8179634 | 0.77 | TLR8 (0.47) | FLT3F2F10CA2NPC1 | |
| SCHEMBL27841947 | 0.77 | MAOA (0.56) | FFAR1FFAR4CYP2C9CACNA1CCA2 | |
| SCHEMBL4689215 | 0.76 | FLT3 (0.55) | FLT3F2F10CA2NPC1 | |
| SCHEMBL16329628 | 0.76 | FLT3 (0.56) | FLT3F2F10CA2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103044370-A | Preparation method of 5-(piperazinyl-1-yl) benzofuranyl-2-carboxamide | SHANDONG ZOUPING DAZHAN NEW MATERIALS CO LTD | 2013-04-17 | — | — | CN | disclosed |
| US-20010034445-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2001-10-25 | — | — | US | disclosed |
| US-6159964-A | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2000-12-12 | — | — | US | disclosed |
| EP-0895475-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2000-08-23 | — | — | EP | disclosed |
| EP-0906103-A4 | — | — | 1999-04-07 | — | — | EP | disclosed |
| EP-0906103-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-07 | — | — | EP | disclosed |
| EP-0895475-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-02-10 | — | — | EP | disclosed |
| US-5739350-A | COMPOUNDS CAPABLE OF BEING LINKED TO MONOCLONAL ANTIBODIES FOR DELIVERY TO TARGET CELLS | PHARMACIA & UPJOHN COMPANY (US) | 1998-04-14 | — | — | US | disclosed |
| WO-1997024122-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-10 | — | — | WO | disclosed |
| WO-1997024124-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-10 | — | — | WO | disclosed |
| EP-0527189-A1 | NOVEL CC-1065 ANALOGS | PHARMACIA & UPJOHN COMPANY (US) | 1993-02-17 | — | — | EP | disclosed |
| WO-1991016324-A1 | NOVEL CC-1065 ANALOGS | THE UPJOHN COMPANY (US) | 1991-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034445-A1 | Vitronectin receptor antagonists | ADGRF1, GPR174, CALCRL | FLT3 3049/4885FFAR1 108/4885FFAR4 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.